Use our account feature to register for a free CLI account. Your new account will allow you to bookmark and organize articles and research for easy reference later - making it simple to keep track of the research that's important to you!
Register / Sign in
Use our account feature to register for a free CLI account. Your new account will allow you to bookmark and organize articles and research for easy reference later - making it simple to keep track of the research that's important to you!
Register / Sign in
close-panel

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Get Notifications

Sign up to receive email updates from Charlotte Lozier Institute.

This field is for validation purposes and should be left unchanged.

Become A Defender of Life

Your donation helps us continue to provide world-class research in defense of life.

DONATE

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Abortion Drugs

Abortion Drugs

80 results

Filter Results By

Filter Applied. Clear All
Reset All Filters
80 results
featured-image
Abortion Drugs

ADF, Consovoy McCarthy sue academic publisher for politically motivated retractions

Attorneys representing 10 scientists ask California court to compel Sage Publications to stick to its contractual obligation, pursue arbitration.

charlotte-lozier-institute Charlotte Lozier Institute
October 3, 2024
Please login to bookmarkClose
featured-image
Abortion Drugs

New Study Reveals Increasing Severity and Frequency of Emergency Department Visits Following Use of Abortion Drugs

A new study published in the International Journal of Epidemiology and Public Health Research by Dr. James Studnicki, Dr. Ingrid Skop, Tessa Cox, and other CLI scholars, reveals the increasing severity and frequency of emergency department visits among Medicaid-eligible women from 17 states where Medicaid pays for abortion following different pregnancy outcomes.

Abortion Drugs

Study finds 75% of women treated at ERs after taking abortion pills rated ‘severe or critical’

Women who visit emergency rooms after taking abortion pills are more likely to be seen for serious medical problems than their cohorts whose pregnancies end with surgical abortions or live births, according to newly released research.

Abortion Drugs

Primer: The Basic Biochemistry of Abortion Pill Reversal

This primer lays out the science behind Abortion Pill Reversal by examining the function of progesterone as a naturally occurring hormone in the female reproductive system, the functions of mifepristone and misoprostol as drugs used in drug-induced abortion, the basic biochemical principle of competitive inhibition, and the disinformation surrounding the role of progesterone in reversing the abortion drug.

featured-image
Abortion Drugs

United Kingdom Data Deficiencies Influencing U.S. FDA Decisions

CLI's VP of Medical Affairs Ingrid Skop, together with Calum Miller, MD, and Kevin Duffy, MPH, recently published an article in Issues in Law & Medicine arguing that decisions by the FDA to pull back regulations on the abortion drug mifepristone in part relied on "flawed studies with significantly undercounted complications" from the U.K.

featured-image
Abortion Drugs

New Study Reveals FDA Relied on Cherrypicked Data to Approve Dangerous Mail-Order Abortion Drugs

A new peer-reviewed article highlights major flaws in the data used by the U.S. Food and Drug Administration (FDA) to remove medical safeguards and in-person administering of abortion drugs. These flaws illustrate the ongoing problem of lack of quality abortion reporting data in the U.S. as well as in the United Kingdom.

Abortion Drugs

Fact Sheet: Three Problems with the FDA’s Abortion Drugs Complications Data

The FDA’s abortion drugs complications data is woefully incomplete. From 2020-2022, the six states that report complications by type of procedure reported 1,004 total complications from drug-induced abortions. Meanwhile, the FDA Adverse Event Reporting System data reflects just 17 unduplicated abortion-related adverse events over this same period.

Abortion Drugs

Filed: CLI Amicus Brief in SCOTUS Case FDA v. Alliance for Hippocratic Medicine

On March 26, SCOTUS will hear oral arguments in the case FDA v. Alliance for Hippocratic Medicine. In the case, AHM argues that the FDA's changes to regulations of the abortion drug mifepristone were "arbitrary and capricious." CLI filed a brief in support of AHM, arguing that abortion with mifepristone is not "safe," that the FDA's loosening of mifepristone regulations makes these safety concerns even worse, and that AHM et al. have standing, since they would suffer concrete injury under the current loosened mifepristone regulations, being at risk of finding themselves complicit in abortion procedures.

Become A Defender of Life

Your donation helps us continue to provide
world-class research in defense of life.

BECOME A PARTNER
cta-image